Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Amortizatization of Intangibles data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 40.98% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $5.5 million, down 43.93%, while the annual FY2025 figure was $5.5 million, 43.93% down from the prior year.
  • Amortizatization of Intangibles reached $1.1 million in Q4 2025 per AMLX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.2 million in Q2 2024 and bottomed at -$98000.0 in Q4 2021.
  • Average Amortizatization of Intangibles over 5 years is $1.6 million, with a median of $1.8 million recorded in 2024.
  • Peak YoY movement for Amortizatization of Intangibles: surged 145250.0% in 2023, then plummeted 52.08% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$98000.0 in 2021, then surged by 1997.96% to $1.9 million in 2022, then soared by 38.28% to $2.6 million in 2023, then tumbled by 30.37% to $1.8 million in 2024, then tumbled by 40.98% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $1.1 million in Q4 2025, $1.2 million in Q3 2025, and $1.5 million in Q2 2025.